This is the authors' abstract. We don't add key points for this paper.
Pretargeted immuno-PET imaging based on the bioorthogonal chemistry between 18 F-labeled Reppe anhydride derivatives and tetrazine conjugates of the EGFR-specific monoclonal antibodies cetuximab and panitumumab was performed. This pretargeting approach yielded high target-to-nontarget ratios. Furthermore, due to the fast clearance rate of the PET probe, the overall radiation burden to nontarget tissues was also substantially decreased.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: